Ann: Ethics Approval for Phase 2 Atopic Dermatitis Study Received, page-120

Happy New Year Botanians.......Delays? Which delays?
Please realize that the study for BTX1801 is being led by the University of Queensland, not Botanix.

The following extract is from Argonaut's commentary on the collaboration (my emphasis):

​

"The research will be led by Professor Matt Cooper and Dr Mark Blaskovich who are experts in the field of antimicrobial drug discovery and development. The group they lead is aptly called the Centre for Super Bug Solutions (CSS). Their particular focus is on antimicrobial resistance and CSS has a library of antimicrobial resistant microorganisms as well as more common microorganisms that can be used to test the effectiveness of BTX 1801 combined with Permetrex®. The CSS scientists are of the view that while CBD shows interesting preliminary results, it will be key to determine the effect CBD has on drug-resistant bacteria and to determine if the bacteria rapidly develops resistance to CBD once exposed to BTX 1801. CSS is an independent organisation, and the funding is from the Australian Government which will make the results independent of BOT initial findings.
Results from this study will help determine the design of a potential clinical study: CSS plan to test CBD on drug-resistant bacteria and more common bacteria, and the results will help determine whether BTX 1801 will then be further tested in a clinical trial. The data from this study will then be used to design the clinical trial and its end points.
The discovery of a new antibiotic compound would be an important milestone for BOT: All bacteria develop resistance to antibiotics over time, but the issue is that not enough new compounds have been developed to replace those that have lost their efficacy over time. If BTX 1801 is proven to be effective anti-biotic, especially if it is effective against drug-resistant bacteria and bacteria treated with BTX 1801 do not rapidly develop resistance to CBD, BTX 1801 has the potential to be a blockbuster drug."

( no wonder they were giving it a 20c valuation )

https://www.botanixpharma.com/wp-co...aboration-with-UQ-in-relation-to-BTX-1801.pdf

IMO the nature of this study ( a collaborative one ) explains the "delays".